As of July 1, Medicare Covers Wegovy for Weight Loss at $50 a Month. The Eligibility List Is Short.

The Centers for Medicare & Medicaid Services has launched the Medicare GLP-1 Bridge program. This temporary initiative allows certain Medicare beneficiaries to access weight-loss medications like Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay. The program runs through December 31, 2027, and operates independently from standard Part D plans. While the price reduction is significant compared to the typical four-figure monthly cost, eligibility remains highly restrictive.

To qualify for this fixed rate, beneficiaries must meet strict criteria regarding body mass index and specific health conditions. For instance, a BMI of 35 or higher qualifies on its own, but lower BMI requirements necessitate documented co-occurring conditions like chronic kidney disease or uncontrolled hypertension. CMS requires these specific health markers to be present at the time therapy starts. Documentation from a physician is mandatory, and there is no formal appeal process if the initial prior authorization is denied.

Crucially, many patients are ineligible for this specific program. Individuals with existing diagnoses of type 2 diabetes, moderate-to-severe obstructive sleep apnea, or specific forms of liver fibrosis are excluded because they already have established coverage pathways through their standard Part D plans. The bridge program also does not count toward annual out-of-pocket maximums or deductible calculations, meaning it functions as a separate financial obligation outside of the existing Medicare structure.

For those who do not qualify for the bridge, standard formulary rules still apply. It is important to review current Part D plan details to see if weight-loss medications are included or if a formulary exception request is possible. Because the rules are precise, verify your BMI records and diagnosis codes with your healthcare provider before attempting to secure coverage through the bridge. This program serves a narrow group of patients rather than providing universal access to weight-loss drugs for all Medicare enrollees.